ENTERA BIO, based in Wellesley Hills, Massachusetts, is focused on the development and commercialization of product candidates that leverage proprietary technology for the oral delivery of large molecule therapeutics.  Recently, drug development has shifted towards the use of peptides, proteins and other large molecules for the treatment of various diseases.  Oral drug delivery leads to higher patient and physician acceptance and provides significantly more flexibility, both in size of dose and number of doses per day, than injectable drugs.  Entera’s proprietary technology facilitates the absorption of large molecules, and protease inhibitors to prevent enzymatic degradation.